‘Medicine Men’ or DC: President of the United States, Donald Trump, director of the National Institute of Health, Jay Bhattacharya, Centers for the Administrator of Services of Medicare and Medicaid Mehmet Oz, Secretary of Health and Health Services Robert F Kennedy JR, and Commissioner for Admissible Food and Credited Drugs: Nathan Howard
Last week, the president of the United States, Donald Trump, raised a problem that was long in process. “In the case after the case, our citizens pay enormously higher prices than other nations pay the same exact pill, from the same factory, subsidizing socialism on board [abroad] With home acceleration prices, “Trump said, questioning why American patients paid more for medicines compared to those in other developed countries. He has then requested the” most favored nation “approach (MFN), than the” most favored nation medical company “, the lowest Pourd Pourd Pourd Pourd Pourd Pould Medic in any other country.
Although the global pharmaceutical industry is dealing with the last directive, the entire plot has not yet been revealed, special for Indian drug manufacturers. Could you indicate an increase in medicine prices in other countries? And how would it affect the specific prices of India, an approach adopted by several multinational companies (MNC) when they will launch patented medications expenses here?
There are still no clear answers, although more ads are anticipated, invading unprecedented tariffs in pharmaceutical imports to the United States. And this, as well as India, and other countries, including China, participate in commercial conversations with the United States.
At the end of this Hidra head, the global pharmaceutical panorama is ready to see some recalibration, according to the observers. And that could include the Indian pharmaceutical industry, with its exports of $ 9 billion to the US.
59 percent
A multinational clutch has already committed new investments towards manufacturing facilities in the United States. Trump expects its directive for the lowest drug prices for Americans by 59 percent to 90 percent. Then, for large manufacturers of Indian medicines sold in the US, the lowest prices of innovative medications will eliminate the less expensive generic drug segment?
Ajay Srivastava, founder of Global Trade Research Initiative, says that the latest directives should not be seen in isolation. Over the years, countries have increased intellectual property rights (DPI) and patent protection problems (discreditation generic) in commercial discussions about medicines, he explains. While external factors cannot be controlled, India should not admit in its conversations of Public Health IP protection, he says. He thought Red Line, he believes, has been violated in the recent commercial agreement signed with the United Kingdom.
However, industry experts argue that the role of the Indian pharmaceutical industry in the supply of affordable generic medicines in the US. UU. It would be key in commercial and rates negotiations. Special since India houses the largest number of facilities regulated by USFDA outside the United States.
Bhavin Mehta, vice president or Export Promotion Council of Pharmaceuticals of India (Pharmexcil), says that the impact on the national industry would be neutral. There are gaps in the generic medicines segment in the US.
The US administration is analyzing the best medications that have maximum value, it says privileged information in the industry, and adds that Indian drug manufacturers are out of that radar. In addition, countries are looking for supply alternatives, so Indian partners will have an advantage, he says.
Global signals
The Trump MFN announcement echoes efforts in its previous mandate as president of the United States. This time he thought, the reactions are less strident. Pharmaceutical research and manufacturers in America (PHRMA), president and executive director, Stephen J UBL, said in a statement that the real reason why US prices are higher is that foreign countries are not paying their fair part and their conduction. “The administration is right when using trade negotiations to force foreign governments to pay their fair part for medicines. American patients should not pay the bill for global innovation.”
“The United States is the only country in the world that allows PBMS [pharmacy benefit managers]Insurers and hospitals take 50 percent of each dollar spent on medications. The amount that goes to intermediaries exceeds the price in Europe. Giving this money directly to patients will reduce their medicine and significant costs will reduce the gap with European prices, “he said.
“The importation of foreign prices from socialist countries would be a bad business for American patients and workers. It would mean less treatments and priests, and would endanger the hundreds of billions that our member companies plan to invest and peel jobs, forcing jobs, forcing innovative medication work,” he added.
With the last parts of the tangle of the rate to come, Indian drug manufacturers see challenges ahead, since the price script is rewritten for the industry.
Posted on May 18, 2025